Literature DB >> 16436782

LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Laurie J Ozelius, Geetha Senthil, Rachel Saunders-Pullman, Erin Ohmann, Amanda Deligtisch, Michele Tagliati, Ann L Hunt, Christine Klein, Brian Henick, Susan M Hailpern, Richard B Lipton, Jeannie Soto-Valencia, Neil Risch, Susan B Bressman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436782     DOI： 10.1056/NEJMc055509

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  218 in total

1.  Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Authors:  R Saunders-Pullman; K Stanley; M San Luciano; M J Barrett; V Shanker; D Raymond; L J Ozelius; S B Bressman
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

2.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

Review 3.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 4.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

5.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

6.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.

Authors:  José M Bravo-San Pedro; Mireia Niso-Santano; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Ana Aiastui-Pujana; Ana Gorostidi; Vicente Climent; Rakel López de Maturana; Rosario Sanchez-Pernaute; Adolfo López de Munain; José M Fuentes; Rosa A González-Polo
Journal:  Cell Mol Life Sci       Date:  2012-07-08       Impact factor: 9.261

Review 7.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

8.  Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.

Authors:  Kyle B Fraser; Mark S Moehle; Roy N Alcalay; Andrew B West
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

9.  Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Miguel Verbitsky; Sergey Kisselev; Barbara M Ross; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Elise Caccappolo; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  Arch Neurol       Date:  2009-12

10.  Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Authors:  R Djaldetti; S Hassin-Baer; M J Farrer; C Vilariño-Güell; O A Ross; V Kolianov; S Yust-Katz; T A Treves; Y Barhum; M Hulihan; E Melamed
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.